• Anti-cancer dream cream shrinks oral tum

    From ScienceDaily@1:317/3 to All on Wednesday, March 30, 2022 22:30:46
    Anti-cancer dream cream shrinks oral tumors
    Researchers find that miR-634 increases the sensitivity of oral squamous
    cell carcinoma to cisplatin

    Date:
    March 30, 2022
    Source:
    Tokyo Medical and Dental University
    Summary:
    Researchers have found that treatment with miR-634 reduces the
    resistance of oral squamous cell carcinoma cells to cisplatin,
    resulting in increased tumor cell killing. An ointment containing
    miR-634 had a similar effect in mice, suggesting that this simple
    topical treatment could be used to improve the prognosis of patients
    with advanced oral cancer.



    FULL STORY ========================================================================== Modern medicine offers "peel and stick" solutions like nicotine or contraceptive patches that you can put right on your skin without needing
    to visit a doctor for an injection or procedure. Now, researchers have
    found that applying a topical ointment containing anti-tumor factor can increase the effectiveness of cancer treatment.


    ==========================================================================
    In a study that will be published soon in Molecular Therapy Oncolytics, researchers from Tokyo Medical and Dental University (TMDU) reveal that treating oral cancer cells with miR-634, a microRNA that targets pro-tumor factors, can increase the effectiveness of treatment with cisplatin.

    Over 90% of cases of oral cancer are a type of cancer called oral squamous
    cell carcinoma (OSCC). While OSCC can be treated with chemotherapy and radiation, many patients develop resistance to cisplatin, the main drug
    used to treat it.

    "We recently found that miR-634 counteracts some cell-protective
    processes, such as anti-apoptotic signaling and antioxidant scavenging,
    that are activated in cancer cells that are resistant to cisplatin,"
    says Phuong Xuan Tran, lead author on the study. "This suggests that
    increasing the amount of this small molecule in cells could increase
    their sensitivity to this drug." To test whether miR-634 can help
    increase tumor sensitivity to cisplatin, the researchers treated two
    different OSCC cell lines with both the miRNA and the drug and looked
    at how many of the cells survived.

    "The results were very clear," states Johji Inazawa, senior author of the study. "Treatment with miR-634 effectively increased cisplatin-induced cytotoxicity and overcame cisplatin resistance in OSCC cells,
    resulting in increased tumor cell killing." To confirm these results,
    the researchers then tested the treatment combination in mice with
    experimental tumors. When the mice were injected with cisplatin and an
    miR-634 ointment was applied to the tumors, the tumors shrank rapidly.

    "Our findings suggest that miR-634-mediated repression of pro-tumor
    factors can effectively increase the sensitivity of OSCC to existing chemotherapeutic options such as cisplatin," says Tran.

    Taken together, the results from this study suggest that miR-634 ointment
    could be useful for enhancing the effects of chemotherapy in patients
    with advanced OSCC. Given that the synergistic effects of miR-634 and
    cisplatin were also seen in esophageal squamous cell carcinoma, bladder
    cancer, and ovarian cancer cell lines, this treatment combination may
    also be effective across a variety of cancer types.


    ========================================================================== Story Source: Materials provided by
    Tokyo_Medical_and_Dental_University. Note: Content may be edited for
    style and length.


    ========================================================================== Journal Reference:
    1. Phuong Xuan Tran, Jun Inoue, Hiroyuki Harada, Johji
    Inazawa. Potential
    for reversing miR-634-mediated cytoprotective processes to
    improve efficacy of chemotherapy against oral squamous cell
    carcinoma. Molecular Therapy - Oncolytics, 2022; 24: 897 DOI:
    10.1016/j.omto.2022.02.002 ==========================================================================

    Link to news story: https://www.sciencedaily.com/releases/2022/03/220330111401.htm

    --- up 4 weeks, 2 days, 10 hours, 51 minutes
    * Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1:317/3)